Capricor Therapeutics, Inc.

As of June 30, 2026, Capricor Therapeutics, Inc. carries a market capitalization of 1.19B, placing it among publicly traded companies globally. Its enterprise value stands at 1.07B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Capricor Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 17, 2026.

As of June 30, 2026, Capricor Therapeutics, Inc. has 58.11M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Capricor Therapeutics, Inc. maintains a current ratio of 7.35, meaning it holds 7.3x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Capricor Therapeutics, Inc. posted a negative return on equity (ROE) of -73.70, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -51.53, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 213.25, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Capricor Therapeutics, Inc. recorded 1,400.48 in income tax expense. The company reported a pretax loss of -113.28M and -113.28M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Capricor Therapeutics, Inc.'s stock has declined approximately 3.51% over the past 52 weeks. The 50-day moving average sits at 7.11, while the 200-day moving average is 17.34.

Over the twelve months ended June 30, 2026, Capricor Therapeutics, Inc. generated - - in revenue and converted that into -113.28M in net income, yielding earnings per share of -2.16. EBITDA reached -41.29M, while operating income came in at -118.30M.

As of June 30, 2026, Capricor Therapeutics, Inc. holds 208.26M in cash and equivalents against 79.69M in total debt, resulting in a net debt position of -18.32M. Total book value stands at 215.52M, with working capital of 183.08M providing operational flexibility.

Capricor Therapeutics, Inc. produced -91.03M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -22.57M in capital expenditures, free cash flow totaled -113.59M - equivalent to -2.16 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -10.53: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -18.04, meaning Capricor Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Capricor Therapeutics, Inc.'s most recent stock split took place on June 5, 2019 with a 10:1 split ratio.

As of June 30, 2026, Capricor Therapeutics, Inc. has an Altman Z-Score of 4.71, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.